Cargando…
Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes
OBJECTIVE: Because of the short potential doubling time of esophageal cancer, there is a theoretical benefit to using an accelerated radiation treatment schedule. This study evaluates outcomes and treatment-related mortality and morbidity of patients treated with neoadjuvant hyperfractionated accele...
Autores principales: | Samuels, Stuart E., Stenmark, Matthew H., Lee, Jae Y., McHugh, Jonathan B., Hayman, James A., Orringer, Mark B., Urba, Susan G., Sun, Libin, Xie, Congying, Kong, Feng-Ming, Cuneo, Kyle C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605317/ https://www.ncbi.nlm.nih.gov/pubmed/29114597 http://dx.doi.org/10.1016/j.adro.2017.05.003 |
Ejemplares similares
-
Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the ‘CROSS-regimen’ in daily practice
por: Cloos-v.Balen, Marissa, et al.
Publicado: (2021) -
Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018) -
Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022) -
Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses
por: Wijnhoven, Bas P. L., et al.
Publicado: (2009) -
Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
por: So, Tsz Him, et al.
Publicado: (2020)